Anusha Kalbasi

@QinliSun @ScienceKyle @Nature Congrats Qinli!

Excited to share our new @Nature paper! We developed an IL-2–TGFβ co-agonist that enables efficient induction of antigen-specific pTregs and establishment of immune tolerance in vivo. An important step toward programmable immune tolerance. rdcu.be/e72lN

Thrilled to share the primary focus of my PhD thesis work, now out in @ScienceMagazine today! We developed Trikines — engineered cytokines that reconfigure receptor complex assembly to reshape signaling directly in endogenous immune cells. doi.org/10.1126/scienc…

@SprakerMDPhD @EvanThomas84 Take a look at details on fractures in manuscript. Some clearly not RT related and w so few fx cases hard to conclude on dosimetry, but with our Stanford study reporting soon hopefully across 2 studies we will reveal any dose parameters. SWOG RCT forthcoming from Jeremy Harris

@EvanThomas84 I agree on the fractures, would be nice to see the dosi. Otherwise, this is a reasonable toxicity profile for a relatively high risk cohort (smokers, some diabetics, 70% lower extremity). Not sure I agree we need an RCT. Pooled analysis of prospective patients would be cool.

Interesting study- they mention patients undergoing electron therapy though….. Which means those would NOT be SBRT treatments. I’d be surprised if wound complication rates were NOT worse in patients receiving electrons. I would love to see treatment planning data from this study. @rickysavjani can you fill us in?

@EvanThomas84 this is an update on our original report of early outcomes data from 50 pts at UCLA pubmed.ncbi.nlm.nih.gov/32054730/ Only 1 or 2 pts if I recall in total were treated with electrons. Vast majority IMRT, a handful 3DCRT. We didn’t call it SBRT, though it is a bit of semantics here.

thanks @JoeFraietta and Janna for having me on!

Two complementary studies from our group out today: a therapeutic peptide vaccine trial for fibrolamellar carcinoma (FLC) & TIRTL-Seq, our robust method for deep quantitative paired TCR sequencing a🧵w/ @MarkYarchoan & @pogorely nature.com/articles/s4159… & nature.com/articles/s4159…

IL-9 enhancement of engineered CAR-T therapies @ImmunityCP @carlhjune @msofiacastelli @Penn @xrtcell @stanford @KaylaKulhanek cell.com/immunity/fullt… cell.com/immunity/fullt…

@SeanPitroda thanks Sean! can't wait to accidentally run into you in another country again.

@xrtcell Congrats!

What if nature already has the optimal cytokine solution for T cell therapy, but we just haven’t found it yet? Check out our paper out today in Immunity on IL-9 as a naturally orthogonal cytokine ideally tuned for T cell therapy authors.elsevier.com/sd/article/S10… 1/9

@EvanWeberPhD thanks Evan!

@xrtcell really cool story Anusha, congrats!

Engineering T cells (CAR T) for treatment of solid cancers has had mixed success to date. Two reports today raise the promise of using interleukin-9 as a way to raise efficacy @ImmunityCP cell.com/immunity/fullt… cell.com/immunity/fullt…

This was a truly collective effort in my lab after moving up to @Stanford with big contributions from everyone. Also not possible without generous collaborators in the Garcia and @Moding labs. 9/9

What’s next? We are working our way to the clinic. And with support from @NIH, @CancerResearch and @parkerici, we are deep under the hood of JAK/STAT signaling in cancer immunotherapy. If you are a prospective post-doc and this work captured your interest, please reach out! 8/9

Please join us in congratulating our department chair, Quynh Le, MD, for receiving the 2025 @ASTRO_org Gold Medal Award. Dr. Le was awarded the Gold Medal during the ASTRO Annual Meeting Award Ceremony yesterday, September 30, 2025.